XENE Valuation Metrics
FCF$-279.92M
FCF Growth Rate—
EPS Growth (CAGR)—
WACC10.00%
Xenon Pharmaceuticals Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications.
Current Price
$54.12
-1.02%Profile
Valuation (TTM)
Market Cap$4.50B
P/E-11.75
EV—
P/B7.74
Shares Out83.19M
P/Sales—
Revenue$0.00
EV/EBITDA—
Xenon Pharmaceuticals Inc (XENE) Valuation
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →XENE Valuation & Fair Value Analysis
Xenon Pharmaceuticals Inc (XENE) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The price-to-earnings (P/E) ratio is -11.75. Price-to-book ratio is 7.74. PEG ratio is -0.29.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Xenon Pharmaceuticals Inc's intrinsic value.